ACT up +1.05% percent Today $ACT High is at 245.00 and the Low 241.69 with current volume of 423,976.
Recent News posted below.
Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - 2 hrs 15 mins ago
ZTS: 43.19 (-0.05), AGN: 197.50 (+1.29), VRX: 132.61 (+0.71), ACT: 243.43 (+1.80)
Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.19 (-0.05), AGN: 197.50 (+1.29), ACT: 243.43 (+1.80), VRX: 132.61 (+0.71)
Mallinckrodt ADHD Drug Hits FDA Trouble; Stock Drops
at Investor's Business Daily - Thu Nov 13, 10:09AM CST
Specialty drugmaker Mallinckrodt (MNK) said Thursday that the FDA is no longer recognizing its generic ADHD drug as equivalent to the original, which would essentially knock it out of the market. Mallinckrodt was down 5.5% in morning trading in the...
IPXL: 28.59 (-0.47), MNK: 85.68 (-1.28), JNJ: 108.48 (-0.59), ACT: 243.43 (+1.80)
FDA to review Actavis' application for Saphris label expansion
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:44AM CST
ACT: 243.43 (+1.80)
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients
PR Newswire - Thu Nov 13, 7:00AM CST
Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' Supplemental New Drug Application (sNDA) for SAPHRIS® (asenapine) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients 10 to 17 years of age. Actavis' sNDA for SAPHRIS has been granted priority review status by the FDA.
ACT: 243.43 (+1.80)
Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 197.50 (+1.29), VRX: 132.61 (+0.71), ACT: 243.43 (+1.80)
New finance chief at Actavis
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:10PM CST
ACT: 243.23 (+1.60)
Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.19 (-0.05), AGN: 197.50 (+1.29), VRX: 132.61 (+0.71), ACT: 243.27 (+1.64)
Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST
AGN: 197.50 (+1.29), ACT: 243.27 (+1.64)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.75 (unch), AGN: 197.50 (+1.29), ACT: 243.27 (+1.64), IRWD: 13.12 (-0.37), CBST: 70.30 (-1.44), PFE: 30.31 (-0.11)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 142.85 (+0.14), ACT: 243.13 (+1.50), CBG: 32.48 (-0.21), HCP: 43.47 (-0.45), BCR: 164.87 (-0.72), PCG: 49.79 (+0.02), AMGN: 158.48 (-2.37), CB: 101.97 (+0.50), SRE: 109.08 (-0.43), PLD: 40.96 (-0.14), HSP: 57.94 (-0.15), TWX: 79.48 (+0.50), KIM: 24.59 (-0.15), CMI: 144.59 (+0.07), ALXN: 188.20 (-5.39), ESS: 199.83 (-0.69), ABBV: 63.30 (-0.33), CAT: 101.38 (+0.27), AAPL: 113.65 (+0.83)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 197.50 (+1.29), VRX: 132.61 (+0.71), ACT: 243.13 (+1.50)
Use Daily, Weekly Charts To See Institutional Buying
at Investor's Business Daily - Tue Nov 11, 4:23PM CST
Plenty of pundits dismiss charts when it comes to helping evaluate a stock's prospects for gains. It's like reading tea leaves, they say, and investors are better off paying attention only to fundamentals and holding for the long term. Cover your...
ACT: 243.13 (+1.50)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 197.50 (+1.29), ZTS: 43.19 (-0.05), ACT: 243.27 (+1.64), VRX: 132.61 (+0.71)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.75 (unch), AGN: 197.50 (+1.29), ACT: 243.27 (+1.64), VRX: 132.61 (+0.71), MDT: 69.18 (-0.20), SLXP: 98.70 (+1.71), SNY: 46.47 (-0.06)
Actavis (ACT) Upgraded From Hold to Buy
at The Street - Tue Nov 11, 8:05AM CST
Actavis (ACT) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
ACT: 243.27 (+1.64)
Actavis elects Maria Teresa (Tessa) Hilado as CFO
M2 - Tue Nov 11, 6:46AM CST
Pharmaceutical company Actavis (NYSE:ACT) disclosed on Monday the addition of Maria Teresa (Tessa) Hilado as its chief financial officer.
ACT: 243.27 (+1.64)
Actavis Names Maria Teresa Hilado Chief Financial Officer
PR Newswire - Mon Nov 10, 3:15PM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Maria Teresa (Tessa) Hilado will join the Company, effective December 8, 2014, as Chief Financial Officer.
ACT: 243.27 (+1.64)
Bulls Rule As Volatility Recedes And Investors Position For Holiday Cheer
Scott Martindale - Seeking Alpha - Mon Nov 10, 9:10AM CST
After displaying a classic V-bottom reversal to what turned out to be a quick and anemic attempt by the bears to bring about a real correction, bullish fervor is becoming contagious, especially as the traditionally strong holiday season approaches....
ACT: 243.27 (+1.64), LUV: 39.02 (-0.44), IYZ: 30.69 (+0.09), SPY: 204.12 (-0.07), IDU: 112.92 (-0.36), AMAT: 22.53 (-0.09), JAZZ: 171.23 (-1.75), IYW: 103.81 (+0.39), FDX: 171.69 (+0.12), IYK: 104.08 (-0.17), IYJ: 106.52 (+0.23), XTN: 102.59 (-0.37), IYH: 141.00 (-1.41), LSTR: 77.02 (+0.51), SWKS: 61.32 (+0.61), IYM: 85.04 (+0.23), IYC: 130.63 (+0.06), NXPI: 72.69 (+0.11), SOXX: 87.16 (+0.05), IYF: 88.12 (+0.10), IYE: 48.73 (+0.39), ADM: 51.03 (+0.22), ARRS: 28.61 (+0.18), PJP: 66.11 (-0.88), ALXN: 188.20 (-5.39)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 66.73 (-0.37), ACT: 243.27 (+1.64), JAZZ: 171.23 (-1.75), UNH: 95.22 (-0.68), CELG: 103.91 (-3.52), CELGZ: 3.25 (+0.07)
Recent News posted below.
Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - 2 hrs 15 mins ago
ZTS: 43.19 (-0.05), AGN: 197.50 (+1.29), VRX: 132.61 (+0.71), ACT: 243.43 (+1.80)
Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.19 (-0.05), AGN: 197.50 (+1.29), ACT: 243.43 (+1.80), VRX: 132.61 (+0.71)
Mallinckrodt ADHD Drug Hits FDA Trouble; Stock Drops
at Investor's Business Daily - Thu Nov 13, 10:09AM CST
Specialty drugmaker Mallinckrodt (MNK) said Thursday that the FDA is no longer recognizing its generic ADHD drug as equivalent to the original, which would essentially knock it out of the market. Mallinckrodt was down 5.5% in morning trading in the...
IPXL: 28.59 (-0.47), MNK: 85.68 (-1.28), JNJ: 108.48 (-0.59), ACT: 243.43 (+1.80)
FDA to review Actavis' application for Saphris label expansion
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:44AM CST
ACT: 243.43 (+1.80)
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients
PR Newswire - Thu Nov 13, 7:00AM CST
Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' Supplemental New Drug Application (sNDA) for SAPHRIS® (asenapine) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients 10 to 17 years of age. Actavis' sNDA for SAPHRIS has been granted priority review status by the FDA.
ACT: 243.43 (+1.80)
Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 197.50 (+1.29), VRX: 132.61 (+0.71), ACT: 243.43 (+1.80)
New finance chief at Actavis
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:10PM CST
ACT: 243.23 (+1.60)
Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.19 (-0.05), AGN: 197.50 (+1.29), VRX: 132.61 (+0.71), ACT: 243.27 (+1.64)
Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST
AGN: 197.50 (+1.29), ACT: 243.27 (+1.64)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.75 (unch), AGN: 197.50 (+1.29), ACT: 243.27 (+1.64), IRWD: 13.12 (-0.37), CBST: 70.30 (-1.44), PFE: 30.31 (-0.11)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 142.85 (+0.14), ACT: 243.13 (+1.50), CBG: 32.48 (-0.21), HCP: 43.47 (-0.45), BCR: 164.87 (-0.72), PCG: 49.79 (+0.02), AMGN: 158.48 (-2.37), CB: 101.97 (+0.50), SRE: 109.08 (-0.43), PLD: 40.96 (-0.14), HSP: 57.94 (-0.15), TWX: 79.48 (+0.50), KIM: 24.59 (-0.15), CMI: 144.59 (+0.07), ALXN: 188.20 (-5.39), ESS: 199.83 (-0.69), ABBV: 63.30 (-0.33), CAT: 101.38 (+0.27), AAPL: 113.65 (+0.83)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 197.50 (+1.29), VRX: 132.61 (+0.71), ACT: 243.13 (+1.50)
Use Daily, Weekly Charts To See Institutional Buying
at Investor's Business Daily - Tue Nov 11, 4:23PM CST
Plenty of pundits dismiss charts when it comes to helping evaluate a stock's prospects for gains. It's like reading tea leaves, they say, and investors are better off paying attention only to fundamentals and holding for the long term. Cover your...
ACT: 243.13 (+1.50)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 197.50 (+1.29), ZTS: 43.19 (-0.05), ACT: 243.27 (+1.64), VRX: 132.61 (+0.71)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.75 (unch), AGN: 197.50 (+1.29), ACT: 243.27 (+1.64), VRX: 132.61 (+0.71), MDT: 69.18 (-0.20), SLXP: 98.70 (+1.71), SNY: 46.47 (-0.06)
Actavis (ACT) Upgraded From Hold to Buy
at The Street - Tue Nov 11, 8:05AM CST
Actavis (ACT) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
ACT: 243.27 (+1.64)
Actavis elects Maria Teresa (Tessa) Hilado as CFO
M2 - Tue Nov 11, 6:46AM CST
Pharmaceutical company Actavis (NYSE:ACT) disclosed on Monday the addition of Maria Teresa (Tessa) Hilado as its chief financial officer.
ACT: 243.27 (+1.64)
Actavis Names Maria Teresa Hilado Chief Financial Officer
PR Newswire - Mon Nov 10, 3:15PM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Maria Teresa (Tessa) Hilado will join the Company, effective December 8, 2014, as Chief Financial Officer.
ACT: 243.27 (+1.64)
Bulls Rule As Volatility Recedes And Investors Position For Holiday Cheer
Scott Martindale - Seeking Alpha - Mon Nov 10, 9:10AM CST
After displaying a classic V-bottom reversal to what turned out to be a quick and anemic attempt by the bears to bring about a real correction, bullish fervor is becoming contagious, especially as the traditionally strong holiday season approaches....
ACT: 243.27 (+1.64), LUV: 39.02 (-0.44), IYZ: 30.69 (+0.09), SPY: 204.12 (-0.07), IDU: 112.92 (-0.36), AMAT: 22.53 (-0.09), JAZZ: 171.23 (-1.75), IYW: 103.81 (+0.39), FDX: 171.69 (+0.12), IYK: 104.08 (-0.17), IYJ: 106.52 (+0.23), XTN: 102.59 (-0.37), IYH: 141.00 (-1.41), LSTR: 77.02 (+0.51), SWKS: 61.32 (+0.61), IYM: 85.04 (+0.23), IYC: 130.63 (+0.06), NXPI: 72.69 (+0.11), SOXX: 87.16 (+0.05), IYF: 88.12 (+0.10), IYE: 48.73 (+0.39), ADM: 51.03 (+0.22), ARRS: 28.61 (+0.18), PJP: 66.11 (-0.88), ALXN: 188.20 (-5.39)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 66.73 (-0.37), ACT: 243.27 (+1.64), JAZZ: 171.23 (-1.75), UNH: 95.22 (-0.68), CELG: 103.91 (-3.52), CELGZ: 3.25 (+0.07)
